BACKGROUND AND OBJECTIVES: Rapid discontinuation of prednisone after kidney transplantation potentially allows for minimization of steroid-related side effects. Although intermediate-term data with rapid discontinuation of prednisone have been promising, concern still exists regarding long-term outcomes. The 10-year experience is reported herein. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Between October 1, 1999 and December 31, 2010, 1241 adult primary kidney transplants (791 living donor and 450 deceased donor) were performed using a protocol in which prednisone is discontinued after postoperative day 5. The 10-year actuarial recipient and graft survival rates and prednisone-related side effects were studied. RESULTS: Ten-year actuarial patient survival was 71% for living donor transplants and 62% for deceased donor transplants; 10-year graft survival was 61% for living donor transplants and 51% for deceased donor transplants, and was comparable to 10-year Scientific Registry of Transplant Recipients national data. Ten-year death-censored graft survival was 79% for living donor transplants and 80% for deceased donor transplants. Ten-year acute rejection rates were 25% for deceased donor transplants and 31% for living donor transplants; 10-year chronic rejection (interstitial fibrosis/tubular atrophy) rates were 39% for deceased donor transplants and 47% for living donor transplants. For nondiabetic recipients of living donor or deceased donor allografts, the incidence of new-onset diabetes was significantly lower than in historical controls on prednisone (P<0.001). We also found significantly reduced rates of cataracts, avascular necrosis, and cytomegalovirus infection in some subgroups. CONCLUSIONS: Prednisone-related side effects can be minimized in a protocol incorporating rapid discontinuation of prednisone for maintenance immunosuppression. Ten-year patient and graft outcomes remain acceptable.
BACKGROUND AND OBJECTIVES: Rapid discontinuation of prednisone after kidney transplantation potentially allows for minimization of steroid-related side effects. Although intermediate-term data with rapid discontinuation of prednisone have been promising, concern still exists regarding long-term outcomes. The 10-year experience is reported herein. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Between October 1, 1999 and December 31, 2010, 1241 adult primary kidney transplants (791 living donor and 450 deceased donor) were performed using a protocol in which prednisone is discontinued after postoperative day 5. The 10-year actuarial recipient and graft survival rates and prednisone-related side effects were studied. RESULTS: Ten-year actuarial patient survival was 71% for living donor transplants and 62% for deceased donor transplants; 10-year graft survival was 61% for living donor transplants and 51% for deceased donor transplants, and was comparable to 10-year Scientific Registry of Transplant Recipients national data. Ten-year death-censored graft survival was 79% for living donor transplants and 80% for deceased donor transplants. Ten-year acute rejection rates were 25% for deceased donor transplants and 31% for living donor transplants; 10-year chronic rejection (interstitial fibrosis/tubular atrophy) rates were 39% for deceased donor transplants and 47% for living donor transplants. For nondiabetic recipients of living donor or deceased donor allografts, the incidence of new-onset diabetes was significantly lower than in historical controls on prednisone (P<0.001). We also found significantly reduced rates of cataracts, avascular necrosis, and cytomegalovirus infection in some subgroups. CONCLUSIONS:Prednisone-related side effects can be minimized in a protocol incorporating rapid discontinuation of prednisone for maintenance immunosuppression. Ten-year patient and graft outcomes remain acceptable.
Authors: Robyn E Boardman; Rita R Alloway; J Wesley Alexander; Joseph F Buell; Michael Cardi; M Roy First; Michael J Hanaway; Rino Munda; Christin C Rogers; Prabir Roy-Chaudhury; Brian Susskind; Jennifer Trofe; E Steve Woodle Journal: Am J Transplant Date: 2005-02 Impact factor: 8.086
Authors: Arthur J Matas; Raja Kandaswamy; Abhinav Humar; William D Payne; David L Dunn; John S Najarian; Rainer W G Gruessner; Kristen J Gillingham; Lois E McHugh; David E R Sutherland Journal: Ann Surg Date: 2004-09 Impact factor: 12.969
Authors: Johannes M M Boots; Maarten H L Christiaans; Elly M Van Duijnhoven; Robert-Jan Van Suylen; Johannes P Van Hooff Journal: Transplantation Date: 2002-12-27 Impact factor: 4.939
Authors: Khalid Khwaja; Massimo Asolati; James V Harmon; J Keith Melancon; Ty B Dunn; Kristen J Gillingham; Raja Kandaswamy; Abhinav Humar; Rainer W G Gruessner; William D Payne; John S Najarian; David L Dunn; David E R Sutherland; Arthur J Matas Journal: Transplantation Date: 2004-11-15 Impact factor: 4.939
Authors: T M Suszynski; K J Gillingham; M D Rizzari; T B Dunn; W D Payne; S Chinnakotla; E B Finger; D E R Sutherland; J S Najarian; T L Pruett; A J Matas; R Kandaswamy Journal: Am J Transplant Date: 2013-02-22 Impact factor: 8.086
Authors: Sapna P Iyer; Lucas E Nikkel; Kyle K Nishiyama; Elzbieta Dworakowski; Serge Cremers; Chiyuan Zhang; Donald J McMahon; Stephanie Boutroy; X Sherry Liu; Lloyd E Ratner; David J Cohen; X Edward Guo; Elizabeth Shane; Thomas L Nickolas Journal: J Am Soc Nephrol Date: 2014-02-07 Impact factor: 10.121
Authors: Kalathil K Sureshkumar; Sabiha M Hussain; Ngoc L Thai; Tina Y Ko; Khaled Nashar; Richard J Marcus Journal: World J Transplant Date: 2014-09-24
Authors: Sunjae Bae; Jacqueline M Garonzik Wang; Allan B Massie; Kyle R Jackson; Mara A McAdams-DeMarco; Daniel C Brennan; Krista L Lentine; Josef Coresh; Dorry L Segev Journal: J Am Soc Nephrol Date: 2019-12-18 Impact factor: 10.121
Authors: Oscar Kenneth Serrano; Raja Kandaswamy; Kristen Gillingham; Srinath Chinnakotla; Ty B Dunn; Erik Finger; William Payne; Hassan Ibrahim; Aleksandra Kukla; Richard Spong; Naim Issa; Timothy L Pruett; Arthur Matas Journal: Transplantation Date: 2017-10 Impact factor: 4.939